Day One Biopharmaceuticals (DAWN) Financials

$6.84 +0.08 (+1.18%)

Closing price 04/17/2025 04:00 PM Eastern

Extended Trading

$6.84 0.00 (-0.07%)

As of 04/17/2025 04:10 PM Eastern

Annual Income Statements for Day One Biopharmaceuticals

This table shows Day One Biopharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-142	-189	-95
Consolidated Net Income / (Loss)	-142	-189	-95
Net Income / (Loss) Continuing Operations	-142	-189	-95
Total Pre-Tax Income	-142	-189	-88
Total Operating Income	-147	-206	-217
Total Gross Profit	0.00	0.00	126
Total Revenue	0.00	0.00	131
Operating Revenue	0.00	0.00	131
Total Cost of Revenue	0.00	0.00	5.28
Operating Cost of Revenue	0.00	0.00	5.28
Total Operating Expenses	147	206	343
Selling, General & Admin Expense	61	76	115
Research & Development Expense	86	131	228
Total Other Income / (Expense), net	4.73	17	129
Interest & Investment Income	4.75	17	128
Other Income / (Expense), net	-0.02	-	1.22
Income Tax Expense	0.00	0.00	7.14
Basic Earnings per Share	($2.17)	($2.37)	($1.02)
Weighted Average Basic Shares Outstanding	65.47M	79.77M	93.23M
Diluted Earnings per Share	($2.17)	($2.37)	($1.02)
Weighted Average Diluted Shares Outstanding	65.47M	79.77M	93.23M
Weighted Average Basic & Diluted Shares Outstanding	73.59M	87.38M	101.35M

This table shows Day One Biopharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-38	-40	-42	-46	-46	-55	-62	-7.26	73	-99
Consolidated Net Income / (Loss)	-38	-40	-42	-46	-46	-55	-62	-4.41	37	-66
Net Income / (Loss) Continuing Operations	-38	-40	-42	-46	-46	-55	-62	-4.41	37	-66
Total Pre-Tax Income	-38	-40	-42	-46	-46	-55	-62	-2.86	36	-59
Total Operating Income	-40	-43	-46	-49	-51	-60	-67	-115	30	-65
Total Gross Profit	0.00	-	0.00	0.00	0.00	-	0.00	7.49	92	26
Total Revenue	0.00	-	0.00	0.00	0.00	-	0.00	8.19	94	29
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.71	1.59	2.98
Total Operating Expenses	40	43	46	49	51	60	67	122	63	92
Selling, General & Admin Expense	18	17	18	17	18	22	27	30	29	30
Research & Development Expense	22	26	28	32	33	37	40	92	34	62
Total Other Income / (Expense), net	1.90	2.63	3.46	3.39	5.29	5.05	4.36	112	6.52	6.09
Interest & Investment Income	1.90	2.66	3.47	3.41	5.29	5.02	4.37	112	5.32	6.05
Other Income / (Expense), net	0.01	-0.03	-0.00	-0.02	-0.00	-	-0.01	-0.01	1.20	0.04
Basic Earnings per Share	($0.53)	($0.56)	($0.59)	($0.61)	($0.54)	($0.63)	($0.72)	($0.05)	$0.38	($0.63)
Weighted Average Basic Shares Outstanding	71.01M	65.47M	71.97M	74.96M	85.95M	79.77M	86.68M	87.12M	96.62M	93.23M
Diluted Earnings per Share	($0.53)	($0.56)	($0.59)	($0.61)	($0.54)	($0.63)	($0.72)	($0.05)	$0.38	($0.63)
Weighted Average Diluted Shares Outstanding	71.01M	65.47M	71.97M	74.96M	85.95M	79.77M	86.68M	87.12M	96.94M	93.23M
Weighted Average Basic & Diluted Shares Outstanding	73.55M	73.59M	73.57M	86.97M	87.04M	87.38M	87.39M	87.76M	100.85M	101.35M

This table details how cash moves in and out of Day One Biopharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Net Change in Cash & Equivalents	-199	146	-106
Net Cash From Operating Activities	-110	-147	-78
Net Cash From Continuing Operating Activities	-110	-147	-78
Net Income / (Loss) Continuing Operations	-142	-189	-95
Consolidated Net Income / (Loss)	-142	-189	-95
Depreciation Expense	0.06	0.04	0.09
Amortization Expense	-1.56	-9.73	-4.45
Non-Cash Adjustments To Reconcile Net Income	27	42	-4.74
Changes in Operating Assets and Liabilities, net	6.56	9.42	26
Net Cash From Investing Activities	-255	128	-231
Net Cash From Continuing Investing Activities	-255	128	-231
Purchase of Property, Plant & Equipment	-0.03	-0.22	-2.17
Acquisitions	0.00	0.00	-17
Purchase of Investments	-394	-444	-659
Sale of Property, Plant & Equipment	0.00	0.00	108
Sale and/or Maturity of Investments	139	575	394
Other Investing Activities, net	0.00	-3.00	-55
Net Cash From Financing Activities	166	164	203
Net Cash From Continuing Financing Activities	166	164	203
Issuance of Common Equity	162	163	201
Other Financing Activities, net	3.65	1.34	2.27
Cash Income Taxes Paid	0.00	0.00	1.90

This table details how cash moves in and out of Day One Biopharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-268	-36	-36	140	52	-10	40	-31	183	-298
Net Cash From Operating Activities	-23	-35	-26	-42	-37	-41	-50	-49	51	-30
Net Cash From Continuing Operating Activities	-23	-35	-26	-42	-37	-41	-50	-49	51	-30
Net Income / (Loss) Continuing Operations	-38	-40	-42	-46	-46	-55	-62	-4.41	37	-66
Consolidated Net Income / (Loss)	-38	-40	-42	-46	-46	-55	-62	-4.41	37	-66
Depreciation Expense	0.04	0.02	0.01	0.01	0.01	0.01	0.02	0.02	0.02	0.04
Amortization Expense	0.13	-1.87	-0.52	-5.17	-2.56	-1.49	-1.20	-0.50	-0.65	-2.10
Non-Cash Adjustments To Reconcile Net Income	7.55	7.86	9.45	9.48	12	11	13	-95	67	11
Changes in Operating Assets and Liabilities, net	6.87	-1.22	7.47	-0.88	-0.68	3.50	1.22	51	-52	27
Net Cash From Investing Activities	-247	-2.21	-11	20	89	30	89	17	-68	-270
Net Cash From Continuing Investing Activities	-247	-2.21	-11	20	89	30	89	17	-68	-270
Purchase of Property, Plant & Equipment	-0.00	-	-0.03	-0.15	-0.04	-0.01	0.00	-0.03	-0.72	-1.42
Purchase of Investments	-267	-121	-160	-105	-80	-99	-47	-122	-215	-275
Sale and/or Maturity of Investments	20	119	149	125	172	130	136	48	203	7.00
Net Cash From Financing Activities	2.05	1.92	1.18	162	0.12	0.60	0.05	1.30	200	1.85
Net Cash From Continuing Financing Activities	2.37	1.92	1.18	162	0.12	0.60	0.05	1.30	200	1.85
Issuance of Common Equity	0.32	0.32	0.00	162	-	0.60	0.00	0.97	199	0.93
Other Financing Activities, net	2.05	1.60	1.18	0.04	0.12	-	0.05	0.32	0.98	0.92
Cash Income Taxes Paid	-	-	-	-	-	-	-	-	-	1.02

This table presents Day One Biopharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2022	2023	2024
Total Assets	349	376	583
Total Current Assets	348	375	562
Cash & Equivalents	85	231	125
Short-Term Investments	257	136	407
Accounts Receivable	-	0.00	14
Inventories, net	-	0.00	3.32
Prepaid Expenses	5.61	8.93	13
Plant, Property, & Equipment, net	0.02	0.21	2.29
Total Noncurrent Assets	1.17	0.57	18
Intangible Assets	-	0.00	16
Other Noncurrent Operating Assets	1.17	0.57	2.54
Total Liabilities & Shareholders' Equity	349	376	583
Total Liabilities	17	30	80
Total Current Liabilities	17	30	73
Accounts Payable	0.26	2.58	3.26
Accrued Expenses	16	27	69
Current Deferred Revenue	-	0.00	1.55
Other Current Liabilities	0.41	0.41	0.01
Total Noncurrent Liabilities	0.41	0.00	6.59
Noncurrent Deferred Revenue	-	0.00	3.23
Other Noncurrent Operating Liabilities	0.41	0.00	3.35
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	332	347	503
Total Preferred & Common Equity	332	347	503
Total Common Equity	332	347	503
Common Stock	602	805	1,057
Retained Earnings	-270	-459	-554
Accumulated Other Comprehensive Income / (Loss)	-0.07	0.01	0.08

This table presents Day One Biopharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	382	324	451	414	327	400	601
Total Current Assets	381	645	450	413	326	383	581
Cash & Equivalents	121	49	189	241	270	240	423
Short-Term Investments	253	269	254	164	48	122	136
Accounts Receivable	-	-	-	-	-	9.14	8.70
Inventories, net	-	-	-	-	-	0.15	2.74
Prepaid Expenses	6.17	4.21	6.90	7.75	8.09	12	11
Plant, Property, & Equipment, net	0.04	0.07	0.18	0.21	0.19	0.20	0.90
Total Noncurrent Assets	1.31	1.10	0.79	0.68	0.26	17	19
Intangible Assets	-	-	-	-	-	17	16
Other Noncurrent Operating Assets	1.31	1.10	0.79	0.68	0.26	0.16	2.69
Total Liabilities & Shareholders' Equity	382	324	451	414	327	400	601
Total Liabilities	19	23	25	25	30	94	45
Total Current Liabilities	18	23	25	24	30	94	40
Accounts Payable	3.97	4.66	4.57	3.39	4.78	6.44	3.02
Accrued Expenses	14	18	20	21	25	87	35
Current Deferred Revenue	-	-	-	-	-	-	1.46
Other Current Liabilities	0.46	0.42	0.43	0.44	0.30	0.19	0.08
Total Noncurrent Liabilities	0.51	0.30	0.19	0.08	0.00	0.00	5.60
Noncurrent Deferred Revenue	-	-	-	-	-	-	3.06
Other Noncurrent Operating Liabilities	0.51	0.30	0.19	0.08	-	-	2.54
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	363	300	426	390	297	307	555
Total Preferred & Common Equity	363	300	426	390	297	307	555
Total Common Equity	363	300	426	390	297	307	555
Common Stock	593	612	784	794	818	832	1,044
Retained Earnings	-230	-312	-358	-404	-521	-525	-488
Accumulated Other Comprehensive Income / (Loss)	-0.39	0.07	-0.01	-0.01	-0.01	-0.02	-0.01

This table displays calculated financial ratios and metrics derived from Day One Biopharmaceuticals' official financial filings.

Metric	2022	2023	2024
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-104.56%	-45.36%	-2.16%
EBIT Growth	-101.94%	-40.25%	-4.85%
NOPAT Growth	-101.96%	-40.27%	-5.44%
Net Income Growth	-95.43%	-32.87%	49.45%
EPS Growth	53.03%	-9.22%	56.96%
Operating Cash Flow Growth	-126.36%	-33.66%	46.81%
Free Cash Flow Firm Growth	31.39%	-40.37%	-6.13%
Invested Capital Growth	-207.21%	-93.62%	-46.26%
Revenue Q/Q Growth	0.00%	0.00%	28.65%
EBITDA Q/Q Growth	-18.06%	-9.31%	-8.05%
EBIT Q/Q Growth	-16.50%	-8.83%	-2.74%
NOPAT Q/Q Growth	-16.46%	-8.86%	-2.75%
Net Income Q/Q Growth	-14.65%	-8.25%	-13.29%
EPS Q/Q Growth	-226.16%	-3.04%	0.00%
Operating Cash Flow Q/Q Growth	-25.24%	-4.31%	12.70%
Free Cash Flow Firm Q/Q Growth	0.00%	-5.33%	11.23%
Invested Capital Q/Q Growth	9.19%	-24.49%	-892.09%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	95.98%
EBITDA Margin	0.00%	0.00%	-168.05%
Operating Margin	0.00%	0.00%	-165.65%
EBIT Margin	0.00%	0.00%	-164.72%
Profit (Net Income) Margin	0.00%	0.00%	-72.81%
Tax Burden Percent	100.00%	100.00%	108.09%
Interest Burden Percent	96.77%	91.68%	40.89%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-46.37%	-55.68%	-22.49%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	-45.07%
Return on Assets (ROA)	0.00%	0.00%	-19.92%
Return on Common Equity (ROCE)	-46.37%	-55.68%	-22.49%
Return on Equity Simple (ROE_SIMPLE)	-42.82%	-54.52%	-18.99%
Net Operating Profit after Tax (NOPAT)	-103	-144	-152
NOPAT Margin	0.00%	0.00%	-115.96%
Net Nonoperating Expense Percent (NNEP)	-12.56%	-12.61%	12.60%
Return On Investment Capital (ROIC_SIMPLE)	-30.97%	-41.62%	-30.25%
Cost of Revenue to Revenue	0.00%	0.00%	4.02%
SG&A Expenses to Revenue	0.00%	0.00%	88.02%
R&D to Revenue	0.00%	0.00%	173.61%
Operating Expenses to Revenue	0.00%	0.00%	261.63%
Earnings before Interest and Taxes (EBIT)	-147	-206	-216
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-148	-216	-220
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.77	3.67	2.54
Price to Tangible Book Value (P/TBV)	4.77	3.67	2.62
Price to Revenue (P/Rev)	0.00	0.00	9.74
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	5.69
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.02	-1.04	-1.06
Leverage Ratio	1.04	1.07	1.13
Compound Leverage Factor	1.01	0.98	0.46
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	54.46	23.43	8.26
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	20.94	12.72	7.66
Quick Ratio	20.60	12.42	7.43
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-96	-135	-143
Operating Cash Flow to CapEx	-422,592.31%	-65,559.38%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.27
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	105.22
Accounts Payable Turnover	0.00	0.00	1.81
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	201.83
Cash Conversion Cycle (CCC)	0.00	0.00	-201.83
Capital & Investment Metrics	-	-	-
Invested Capital	-10	-20	-29
Invested Capital Turnover	0.00	0.00	-5.38
Increase / (Decrease) in Invested Capital	-6.90	-9.58	-9.16
Enterprise Value (EV)	1,241	904	746
Market Capitalization	1,583	1,271	1,278
Book Value per Share	$4.51	$3.98	$4.99
Tangible Book Value per Share	$4.51	$3.98	$4.83
Total Capital	332	347	503
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-342	-366	-532
Capital Expenditures (CapEx)	0.03	0.22	-106
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-11	-21	-43
Debt-free Net Working Capital (DFNWC)	331	346	489
Net Working Capital (NWC)	331	346	489
Net Nonoperating Expense (NNE)	39	45	-57
Net Nonoperating Obligations (NNO)	-342	-366	-532
Total Depreciation and Amortization (D&A)	-1.50	-9.70	-4.36
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	-32.66%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	372.73%
Net Working Capital to Revenue	0.00%	0.00%	372.73%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($2.17)	($2.37)	($1.02)
Adjusted Weighted Average Basic Shares Outstanding	65.47M	79.77M	93.23M
Adjusted Diluted Earnings per Share	($2.17)	($2.37)	($1.02)
Adjusted Weighted Average Diluted Shares Outstanding	65.47M	79.77M	93.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	73.59M	87.38M	101.35M
Normalized Net Operating Profit after Tax (NOPAT)	-103	-144	-152
Normalized NOPAT Margin	0.00%	0.00%	-115.96%
Pre Tax Income Margin	0.00%	0.00%	-67.36%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Day One Biopharmaceuticals' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-106.03%	-103.62%	-67.42%	-48.79%	-36.59%	-36.69%	-46.55%	-111.82%	155.94%	-10.44%
EBIT Growth	-106.35%	-94.72%	-65.26%	-34.18%	-29.61%	-39.16%	-45.61%	-133.04%	159.94%	-9.70%
NOPAT Growth	-106.33%	-36.14%	-65.26%	-34.14%	-29.57%	-39.24%	-45.60%	-133.09%	184.32%	-9.77%
Net Income Growth	-96.44%	-82.81%	-52.78%	-25.55%	-22.11%	-35.91%	-47.22%	90.39%	180.25%	-20.55%
EPS Growth	-60.61%	-116.82%	-22.92%	-1.67%	-1.89%	-12.50%	-22.03%	91.80%	170.37%	0.00%
Operating Cash Flow Growth	-89.95%	-168.13%	-20.51%	-42.45%	-59.66%	-17.17%	-91.38%	-15.78%	236.93%	27.47%
Free Cash Flow Firm Growth	-14.53%	0.00%	-1,985.54%	-11.06%	-95.85%	-39.38%	182.15%	-91.66%	155.38%	-13.98%
Invested Capital Growth	-2,300.20%	-207.21%	9,838.62%	-297.54%	-41.24%	-93.62%	-106.99%	-228.33%	81.65%	-46.26%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,044.54%	-68.85%
EBITDA Q/Q Growth	-8.03%	-12.89%	-8.88%	-17.40%	0.83%	-12.97%	-14.34%	-69.68%	126.19%	-323.02%
EBIT Q/Q Growth	-8.09%	-7.76%	-7.22%	-7.44%	-4.41%	-15.70%	-12.16%	-71.94%	126.85%	-311.76%
NOPAT Q/Q Growth	-8.12%	-7.67%	-7.28%	-7.41%	-4.43%	-15.71%	-12.18%	-71.95%	137.78%	-250.64%
Net Income Q/Q Growth	-3.46%	-6.12%	-5.69%	-8.19%	-0.63%	-18.12%	-14.49%	92.94%	940.41%	-277.43%
EPS Q/Q Growth	11.67%	-5.66%	-5.36%	-3.39%	11.48%	-16.67%	-14.29%	93.06%	860.00%	-265.79%
Operating Cash Flow Q/Q Growth	22.07%	-52.11%	26.41%	-63.29%	12.65%	-11.62%	-20.20%	1.21%	203.31%	-159.13%
Free Cash Flow Firm Q/Q Growth	18.73%	-43.77%	-1,376.32%	93.56%	-43.31%	-2.31%	970.17%	-115.02%	141.41%	-310.56%
Invested Capital Q/Q Growth	-166.12%	9.19%	3,077.75%	-105.52%	5.45%	-24.49%	-7.56%	-159.34%	94.72%	-892.09%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	91.37%	98.30%	89.79%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,407.54%	32.21%	-230.61%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,401.45%	31.61%	-223.68%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1,401.57%	32.88%	-223.54%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-53.80%	39.50%	-224.99%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	154.36%	102.44%	110.93%
Interest Burden Percent	95.23%	93.78%	92.44%	93.09%	89.71%	91.59%	93.46%	2.49%	117.26%	90.73%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2.44%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-37.54%	-46.37%	-56.01%	-40.69%	-46.37%	-55.68%	-69.97%	-45.71%	-17.84%	-22.49%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-138.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-26.98%	6.61%	-61.16%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-1.04%	7.94%	-61.55%
Return on Common Equity (ROCE)	-37.54%	-46.37%	-56.01%	-40.69%	-46.37%	-55.68%	-69.97%	-45.71%	-17.84%	-22.49%
Return on Equity Simple (ROE_SIMPLE)	-34.16%	0.00%	-52.20%	-39.00%	-44.79%	0.00%	-70.39%	-54.60%	-15.18%	0.00%
Net Operating Profit after Tax (NOPAT)	-28	-30	-32	-34	-36	-42	-47	-80	30	-46
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-981.02%	32.38%	-156.57%
Net Nonoperating Expense Percent (NNEP)	-2.98%	-3.25%	-7.96%	-2.72%	-2.60%	-3.63%	-9.99%	18.87%	1.39%	-4.45%
Return On Investment Capital (ROIC_SIMPLE)	-	-9.01%	-	-	-	-12.02%	-	-	-	-9.10%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8.63%	1.70%	10.21%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	368.48%	30.90%	101.80%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,124.34%	35.80%	211.66%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1,492.82%	66.70%	313.47%
Earnings before Interest and Taxes (EBIT)	-40	-43	-46	-49	-51	-60	-67	-115	31	-65
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-40	-45	-46	-54	-54	-61	-68	-115	30	-67
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.05	4.77	3.28	2.06	2.74	3.67	4.84	3.93	2.20	2.54
Price to Tangible Book Value (P/TBV)	4.05	4.77	3.28	2.06	2.74	3.67	4.84	4.15	2.27	2.62
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	147.00	11.99	9.74
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	2.19	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	102.83	6.51	5.69
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	6.70	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-1.02	-1.02	-0.46	-1.03	-1.04	-1.04	-0.53	-1.10	-1.02	-1.06
Leverage Ratio	1.04	1.04	1.06	1.05	1.06	1.07	1.09	1.16	1.07	1.13
Compound Leverage Factor	0.99	0.98	0.98	0.97	0.95	0.98	1.02	0.03	1.26	1.02
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	46.95	55.44	25.99	21.00	25.43	24.71	27.09	5.82	16.46	9.11
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	20.83	20.94	28.22	18.35	16.89	12.72	10.93	4.09	14.62	7.66
Quick Ratio	20.49	20.60	13.93	18.07	16.57	12.42	10.66	3.96	14.27	7.43
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-16	-23	-340	-22	-31	-32	279	-42	17	-37
Operating Cash Flow to CapEx	-580,350.00%	0.00%	-99,942.31%	-28,477.85%	-90,400.00%	-517,150.00%	0.00%	-188,957.69%	7,010.08%	-2,114.73%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.20	0.27
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	43.23	182.55	105.22
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.13	0.72	1.81
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2,841.79	509.12	201.83
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2,841.79	-509.12	-201.83
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-11	-10	305	-17	-16	-20	-21	-55	-2.92	-29
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.23	-10.83	-5.38
Increase / (Decrease) in Invested Capital	-12	-6.90	308	-13	-4.65	-9.58	-326	-38	13	-9.16
Enterprise Value (EV)	1,097	1,241	666	436	662	904	1,120	842	664	746
Market Capitalization	1,471	1,583	984	878	1,067	1,271	1,438	1,204	1,223	1,278
Book Value per Share	$4.94	$4.51	$4.08	$5.79	$4.48	$3.98	$3.42	$3.51	$6.33	$4.99
Tangible Book Value per Share	$4.94	$4.51	$4.08	$5.79	$4.48	$3.98	$3.42	$3.32	$6.14	$4.83
Total Capital	363	332	300	426	390	347	297	307	555	503
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-374	-342	-318	-443	-406	-366	-318	-362	-558	-532
Capital Expenditures (CapEx)	0.00	0.00	0.03	0.15	0.04	0.01	0.00	0.03	0.72	1.42
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-12	-11	304	-18	-17	-21	-22	-72	-17	-43
Debt-free Net Working Capital (DFNWC)	362	331	622	425	389	346	296	289	541	489
Net Working Capital (NWC)	362	331	622	425	389	346	296	289	541	489
Net Nonoperating Expense (NNE)	10	10	10	11	10	13	16	-76	-6.68	20
Net Nonoperating Obligations (NNO)	-374	-342	4.21	-443	-406	-366	-318	-362	-558	-532
Total Depreciation and Amortization (D&A)	0.17	-1.85	-0.51	-5.17	-2.55	-1.47	-1.18	-0.49	-0.63	-2.06
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-883.96%	-16.80%	-32.66%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3,533.35%	530.88%	372.73%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3,533.35%	530.88%	372.73%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.53)	($0.56)	($0.59)	($0.61)	($0.54)	($0.63)	($0.72)	($0.05)	$0.38	($0.63)
Adjusted Weighted Average Basic Shares Outstanding	71.01M	65.47M	71.97M	74.96M	85.95M	79.77M	86.68M	87.12M	96.62M	93.23M
Adjusted Diluted Earnings per Share	($0.53)	($0.56)	($0.59)	($0.61)	($0.54)	($0.63)	($0.72)	($0.05)	$0.38	($0.63)
Adjusted Weighted Average Diluted Shares Outstanding	71.01M	65.47M	71.97M	74.96M	85.95M	79.77M	86.68M	87.12M	96.94M	93.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	73.55M	73.59M	73.57M	86.97M	87.04M	87.38M	87.39M	87.76M	100.85M	101.35M
Normalized Net Operating Profit after Tax (NOPAT)	-28	-30	-32	-34	-36	-42	-47	-80	21	-46
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-981.02%	22.13%	-156.57%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-34.85%	38.56%	-202.82%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Day One Biopharmaceuticals' Financials

When does Day One Biopharmaceuticals's financial year end?

According to the most recent income statement we have on file, Day One Biopharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Day One Biopharmaceuticals' net income changed over the last 2 years?

Day One Biopharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$95.50 million in 2024, falling from -$142.18 million in 2022. The previous period was -$188.92 million in 2023.

What is Day One Biopharmaceuticals's operating income?

Day One Biopharmaceuticals's total operating income in 2024 was -$217.27 million, based on the following breakdown:

Total Gross Profit: $125.88 million
Total Operating Expenses: $343.15 million

How has Day One Biopharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Day One Biopharmaceuticals' total revenue changed from $0.00 in 2022 to $131.16 million in 2024, a change of 13,116,100,000.0%.

How much debt does Day One Biopharmaceuticals have?

Day One Biopharmaceuticals' total liabilities were at $80.04 million at the end of 2024, a 171.2% increase from 2023, and a 370.2% increase since 2022.

How much cash does Day One Biopharmaceuticals have?

In the past 2 years, Day One Biopharmaceuticals' cash and equivalents has ranged from $85.26 million in 2022 to $230.78 million in 2023, and is currently $124.97 million as of their latest financial filing in 2024.

How has Day One Biopharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Day One Biopharmaceuticals' book value per share changed from 4.51 in 2022 to 4.99 in 2024, a change of 10.4%.

Related Companies

This page (NASDAQ:DAWN) was last updated on 4/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Day One Biopharmaceuticals (DAWN) Financials

Frequently Asked Questions About Day One Biopharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Day One Biopharmaceuticals (DAWN) Financials

Annual Income Statements for Day One Biopharmaceuticals

Quarterly Income Statements for Day One Biopharmaceuticals

Annual Cash Flow Statements for Day One Biopharmaceuticals

Quarterly Cash Flow Statements for Day One Biopharmaceuticals

Annual Balance Sheets for Day One Biopharmaceuticals

Quarterly Balance Sheets for Day One Biopharmaceuticals

Annual Metrics and Ratios for Day One Biopharmaceuticals

Quarterly Metrics and Ratios for Day One Biopharmaceuticals

Frequently Asked Questions About Day One Biopharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools